BMY: Bull Flag detected on 4 Sep 2026

BMY has formed a bull flag pattern at $68.09, just 0.01% below key resistance, with strong structure (13.5/15) and solid breakout quality (13.0/13). The pattern consolidated within a tight range after rallying 21.6% over three months, positioning within the upper 65.5% of its 52-week range. Volume has compressed to 74% of average, typical for flag consolidation. Overall pattern score of 76 and 73.85% win probability indicate a high-conviction setup ready for directional resolution.

BMY crushed Q2 earnings on July 30, posting $12.97B revenue (up 6% YoY) and $2.04 EPS versus $11.75B and $1.59 expected. Management raised full-year guidance to $49-50B revenue and $6.75-7.00 EPS from prior $46-47.5B and $6.05-6.35. Eliquis soared 22% in Q2 with full-year growth now projected 20-25% versus prior 10-15% guidance. Pivotal H2 2026 readouts for milvexian and Cobenfy are set to define growth trajectory. FDA decision on Camzyos adolescent indication targeted September 30, 2026. Strong earnings beat, aggressive guidance raise, and near-term clinical catalysts provide bullish fundamental backdrop for technical breakout.

A successful bull flag breakout targets $70.34 (measured move), representing a 3.3% gain from current price with resistance at $68.10 already tested. Historically, flag breakouts carry 73.85% win probability per the setup score. Volume confirmation will be critical—the pattern currently trades 26% below average, so a 15-20% volume surge above 8.2M shares would validate upside conviction. Invalidation occurs below $63.00 support, representing a 7.5% downside risk. The relatively low beta of 0.73 suggests controlled volatility even if the breakout executes.

BMY paused enrollment in zola-cel trials due to safety concerns, a potential pipeline drag. RSI at 64.11 shows strength but not overbought conditions—room remains for further advance. Recent volume ratio of 0.74 is below average, indicating potential follow-through conviction risk if volume doesn't expand at breakout. Analysts express caution regarding long-term growth and potential patent issues. The upcoming Camzyos PDUFA decision on September 30 introduces binary event risk; negative FDA action could trigger rapid liquidation below the $63 support level. Regulatory and clinical execution risk on multiple programs remains the primary threat to this pattern setup.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.